Literature DB >> 31055664

Clinical significance of traditional clinical parameters and inflammatory biomarkers for the prognosis of patients with spinal chondrosarcoma: a retrospective study of 150 patients in a single center.

Kehan Xu1, Bo Li1, Quan Huang1, Dongjie Jiang1, Haitao Sun1, Nanzhe Zhong1, Wei Wan2, Haifeng Wei3, Jianru Xiao4.   

Abstract

BACKGROUND: To investigate the clinical significance of five inflammatory biomarkers and conventional clinical parameters in prognostic prediction of spinal chondrosarcoma.
METHODS: Univariate and multivariate analyses were performed to investigate independent prognostic factors for recurrence and death of patients with spinal chondrosarcoma. Disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier curve, and differences were analyzed by log-rank test. The optimal cutoff values for NLR, PLR, LMR, and CAR were determined by X-tile program.
RESULTS: The optimal cutoff value for NLR, PLR, LMR, AGR, and CAR was 2.7, 200, 3.0, 1.5, and 0.2, respectively. Of the 150 patients included, recurrence was detected in 105 patients, and death occurred in 78 patients. Multivariate analysis indicated that Tomita I-III, total resection, and CAR < 0.2 were significantly associated with longer DFS. Meanwhile, preoperative Frankel score D-E, total resection, and CAR < 0.2 were favorable prognostic factors for OS. Subtype analysis showed that only total resection was an independent prognostic factor for DFS of recurrent spinal chondrosarcoma.
CONCLUSION: Total resection could significantly reduce the recurrence rate of spinal chondrosarcoma and improve OS of chondrosarcoma patients. Tomita classification I-III was a favorable factor for DFS, and preoperative Frankel score A-C was an adverse prognostic factor for OS. CAR was the most robust prognostic indicator with a discriminatory ability as compared with other inflammatory indicators. These slides can be retrieved under Electronic Supplementary Material.

Entities:  

Keywords:  Disease-free survival; Inflammatory biomarkers; Overall survival; Prognosis; Spinal chondrosarcoma

Mesh:

Substances:

Year:  2019        PMID: 31055664     DOI: 10.1007/s00586-019-05993-4

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  44 in total

1.  Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P C W Hogendoorn; N Athanasou; S Bielack; E De Alava; A P Dei Tos; S Ferrari; H Gelderblom; R Grimer; K Sundby Hall; B Hassan; P C W Hogendoorn; H Jurgens; M Paulussen; L Rozeman; A H M Taminiau; J Whelan; D Vanel
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  K-ras activation generates an inflammatory response in lung tumors.

Authors:  H Ji; A M Houghton; T J Mariani; S Perera; C B Kim; R Padera; G Tonon; K McNamara; L A Marconcini; A Hezel; N El-Bardeesy; R T Bronson; D Sugarbaker; R S Maser; S D Shapiro; K-K Wong
Journal:  Oncogene       Date:  2006-03-30       Impact factor: 9.867

3.  Surgical strategy for spinal metastases.

Authors:  K Tomita; N Kawahara; T Kobayashi; A Yoshida; H Murakami; T Akamaru
Journal:  Spine (Phila Pa 1976)       Date:  2001-02-01       Impact factor: 3.468

4.  Chondrosarcoma of the mobile spine: report on 22 cases.

Authors:  S Boriani; F De Iure; S Bandiera; L Campanacci; R Biagini; M Di Fiore; L Bandello; P Picci; P Bacchini
Journal:  Spine (Phila Pa 1976)       Date:  2000-04-01       Impact factor: 3.468

Review 5.  The clinical management of chondrosarcoma.

Authors:  Richard F Riedel; Nicole Larrier; Leslie Dodd; David Kirsch; Salutario Martinez; Brian E Brigman
Journal:  Curr Treat Options Oncol       Date:  2009-02-24

6.  Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors.

Authors:  P Lissoni; F Brivio; L Fumagalli; G Messina; V Ghezzi; L Frontini; L Giani; M Vaghi; A Ardizzoia; G S Gardani
Journal:  Int J Biol Markers       Date:  2004 Apr-Jun       Impact factor: 2.659

Review 7.  The clinical approach towards chondrosarcoma.

Authors:  Hans Gelderblom; Pancras C W Hogendoorn; Sander D Dijkstra; Carla S van Rijswijk; Augustinus D Krol; Antonie H M Taminiau; Judith V M G Bovée
Journal:  Oncologist       Date:  2008-03

Review 8.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

9.  Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database.

Authors:  Angela Ylenia Giuffrida; Jorge E Burgueno; Leonidas G Koniaris; Juan C Gutierrez; Robert Duncan; Sean P Scully
Journal:  J Bone Joint Surg Am       Date:  2009-05       Impact factor: 5.284

10.  Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer.

Authors:  Sead Crnalic; Christer Hildingsson; Pernilla Wikström; Anders Bergh; Richard Löfvenberg; Anders Widmark
Journal:  Acta Orthop       Date:  2011-06-10       Impact factor: 3.717

View more
  2 in total

1.  Prognostic Value of Pretreated Blood Inflammatory Markers in Patients with Bone Sarcoma: A Meta-Analysis.

Authors:  Min Jiang; Shaowei Ma; Zhongyan Hua; Zhiying Zhao; Song Gao
Journal:  Dis Markers       Date:  2021-04-08       Impact factor: 3.434

2.  Prognostic value of neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte ratios and Glasgow prognostic score in osteosarcoma: A meta-analysis.

Authors:  Li-Peng Peng; Jie Li; Xian-Feng Li
Journal:  World J Clin Cases       Date:  2022-03-06       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.